

Ticker: **Vtrs US EQUITY**

Viatrix Inc (NASDAQ GS: VTRS, Currency: USD)

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website: www.viatrix.com/en
 Number of Employees: 37,000
 Ticker: VTRS US


1000 Mylan Blvd Canonsburg, PA 15317 United States
 Phone : 1-724-514-1800
 Fax : --

10.40 +0.07 (0.68%)

Viatrix Inc. opera como una empresa farmacéutica. Produce medicamentos para pacientes en varias áreas terapéuticas principales que abarcan enfermedades no transmisibles e infecciosas. Atiende a pacientes en todo el mundo.

Stock Quote & Chart (Currency: USD)			
Last (delayed quote)	10.40	Market Cap (MM)	12,469.9
Open	10.45	Shares Out. (MM)	1,199.0
Previous Close	10.33	Float %	99.6%
Change	-0.15	Shares sold short (MM)	25,932,706.0
Change %	-1.43	Dividend Yield %	4.6
Day High/Day Low	10.5 / 10.3	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	12.4 / 8.4	P / Diluted EPS Before XO	
Volume (MM)	8.01	Beta	0.99
Avg. Vol - 3 mo (MM)	9.28		

Financial Information (Currency: USD, in mm)			
Revenue - LTM	15,800.1	Cash & ST Invest.	1,295
EBIT - LTM	1,307.3	Total Assets	50,022.2
EBITDA - LTM	4,328.9	Total Debt	19,536.3
Net Income - LTM	1,904.1	Total Liabilities	28,949.9
Total Enterprise Value	30,967	Total Equity	21,072.3
TEV/ Total Revenue	1.9 x	Cash from Operations - LTM	2,785.3
TEV/ EBITDA	6.9 x	Cash From Investing - LTM	837.9
		Cash from Financing -LTM	-3,869.9



Company Notes	
	a gain of \$1.000 from Legal/Litigation/Settlement
2013 Q2	GAAP Net Income includes, (in millions, pre-tax): a loss of \$1.00 from Litigation
2013 Q1	GAAP Net Income includes, (in millions, pre-tax): a loss of \$3.00 from Litigation
2012 Q3	GAAP Net Income includes, (in millions, pre-tax): a loss of \$4,098.00 from Litigation
2011 A1	GAAP Net Income includes, (in millions, pre-tax): a loss of \$7.00 from Litigation
2011 Q4	GAAP Net Income includes, (in millions, pre-tax): a loss of \$1.00 from Litigation
2011 Q2	GAAP Net Income includes, (in millions, pre-tax): A loss of \$6.000 from Litigation
2010 A1	GAAP Net Income includes, (in millions, pre-tax): a gain of \$45.00 from Litigation

Key Board Members			
Name	Title	Organization	
1 W Don Cornwell	Co-Founder	Granite Broadcasting Corp	
2	Board Member	Viatrix Inc	
3	Board Member	American Intl Group Inc	
4	Trustee	Edna Mcconnell Clark Foundatio	
5 James Marshall Kilts "Jim"	Founding Partner	Centerview Partners	
6	Founding Partner/Co-Founder	Centerview Capital Holdings LI	
7	Chairman	Advantage Solutions Inc	
8	Board Member	Viatrix Inc	
9	Chairman	Simply Good Foods Co/The	
#	Trustee	University Of Chicago	
#	Board Member	Cato Inst	
# Elisha W Finney	Board Member	Viatrix Inc	
#	Board Member	Mettler-Toledo Intl Inc	
#	Board Member	Nanostring Technologies Inc	
#	Board Member	Icu Medical Inc	
# Harry A Korman "Hal"	Board Member	Viatrix Inc	
# Joellen Lyons Dillon	Board Member	Viatrix Inc	
# Melina E Higgins	Chairman	Antares Capital Corp	
#	Chairman	Antares Capital Lp	
#	Chairman	Genworth Financial Inc	
#	Board Member	Viatrix Inc	
# Robert J Coury	Founder	Coury Consulting Lp	
#		Mylan Pharmaceuticals	
#	Founder	Coury Financial Group Inc	
#	Trustee	Children'S Hospital Of Los Ang	
# Mark W Parrish	Senior Advisor	Frazier Management Lc	
#	President/Ceo	Intl Federation Of Pharmacutca	
#	Chairman	Safecor Health Llc	
#	Vice Chairman	Viatrix Inc	

Ticker: Vtrs US EQUITY


Viatris Inc

Period Type: Annuals

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos


Annuals	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY
Key Financials											
	Actuals						LTM		Estimates		
For the Fiscal Period Ending	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/03/2023	31/03/2023	31/12/2023	31/12/2024	31/12/2025
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Total Revenue	11,076.9	11,907.7	11,433.9	11,500.5	11,946.0	17,886.3	16,262.7	3,729.1	16,262.7	3,866.9	3,866.9
Growth Over Prior Year	17.5%	7.5%	(4.0%)	0.6%	3.9%	49.7%	(9.1%)	(10.5%)	(6.1%)	(6.1%)	(6.1%)
Gross Profit	4,697.0	4,783.1	4,001.6	3,897.6	3,796.7	5,575.5	6,497.0	6,268.0	--	--	--
Margin %	42.4%	40.2%	35.0%	33.9%	31.8%	31.2%	40.0%	168.1%	--	--	--
EBITDA	2,224.6	3,242.9	3,015.5	2,822.4	2,086.0	4,570.1	4,733.4	4,328.9	1,256.0	1,256.0	1,256.0
Margin %	20.1%	27.2%	26.4%	24.5%	17.5%	25.6%	29.1%	116.1%	7.7%	32.5%	32.5%
EBIT	701.6	1,437.1	905.6	715.5	(210.8)	(34.0)	1,614.9	1,307.3	1,177.8	1,177.8	1,177.8
Margin %	6.3%	12.1%	7.9%	6.2%	(1.8%)	(0.2%)	9.9%	35.1%	7.2%	30.5%	30.5%
Earnings from Cont. Ops.	480.0	696.0	352.5	16.8	(669.9)	(1,269.1)	2,078.6	1,904.1	--	--	--
Margin %	4.3%	5.8%	3.1%	0.1%	(5.6%)	(7.1%)	12.8%	51.1%	--	--	--
Net Income	480.0	696.0	352.5	16.8	(669.9)	(1,269.1)	2,078.6	1,904.1	850.3	850.3	850.3
Margin %	4.3%	5.8%	3.1%	0.1%	(5.6%)	(7.1%)	12.8%	51.1%	5.2%	22.0%	22.0%
Diluted EPS Excl. Extra Items	0.9	1.3	0.7	0.0	(1.1)	(1.1)	1.7	1.6	0.7	0.7	0.7
Growth Over Prior Year	(45.9%)	41.3%	(47.7%)	(95.6%)	--	5.4%	--	1,021.4%	(18.8%)	(18.8%)	(18.8%)

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	10.40
Shares Out.	1,199.03
Market Capitalization (USD)	12,469.91
- Cash & Short Term Investments	542.60
+ Total Debt	19,039.40
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
= Total Enterprise Value (USD)	30,966.71
Book Value of Common Equity	20,927.90
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	19,039.40
= Total Capital	39,967.30



Valuation Multiples based on Current Capitalization					
For the Fiscal Period Ending	Actual	LTM	Estimates		
	31/03/2023	31/03/2023	31/03/2023	31/03/2023	31/03/2023
TEV/Total Revenue	2.0x	1.9x	7.7x	7.7x	7.7x
TEV/EBITDA	6.7x	6.9x	5.8x	5.8x	5.8x
TEV/EBIT	19.6x	23.0x	6.1x	6.1x	6.1x
P/Diluted EPS Before Extra	6.5x	6.1x			
P/BV	0.6x	0.6x	0.6x	0.6x	0.6x
Price/Tang BV	--	--			

Valuation Multiples for Chart				
For the Fiscal Period Ending	TTM	FY1	NTM	FY2
PE Ratio	6.1x	3.6x	3.6x	3.6x
TEV / EBITDA	6.9x	5.8x	5.8x	5.8x
Price / CF	4.5x	0.0x	0.0x	0.0x
Price / Book	0.6x	0.6x	0.6x	0.6x
Dividend Yield	4.6x	4.9x	4.9x	4.9x



Ticker:	Vtrs US EQUITY
Period Type	Annuals

Vtrs US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY
Income Statement											
Income Sheet as of:	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Revenue	6,750.20	6,856.60	7,646.50	9,362.60	10,967.10	11,760.00	11,268.70	11,370.30	11,819.90	17,813.60	16,218.10
Other Revenue	45.90	52.50	73.10	66.70	109.80	147.70	165.20	130.20	126.10	72.70	44.60
Total Revenue	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70
Cost Of Goods Sold	3,887.80	3,868.80	4,191.60	5,213.20	6,379.90	7,124.60	7,432.30	7,602.90	8,149.30	12,310.80	9,765.70
Gross Profit	2,908.30	3,040.30	3,528.00	4,216.10	4,697.00	4,783.10	4,001.60	3,897.60	3,796.70	5,575.50	6,497.00
Selling General & Admin Exp.	1,397.60	1,397.00	1,593.60	2,083.30	3,168.60	2,562.70	2,391.50	2,542.20	3,452.40	4,858.40	4,183.50
R & D Exp.	401.30	507.80	581.80	671.90	826.80	783.30	704.50	639.90	555.10	751.10	662.20
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	36.40
Operating Expense, Total	1,798.90	1,904.80	2,175.40	2,755.20	3,995.40	3,346.00	3,096.00	3,182.10	4,007.50	5,609.50	4,882.10
Operating Income	1,109.40	1,135.50	1,352.60	1,460.90	701.60	1,437.10	905.60	715.50	(210.80)	(34.00)	1,614.90
Interest Expense	308.70	313.30	333.20	339.40	454.80	534.60	542.30	517.30	497.80	636.20	592.40
Interest Income	-	-	-	-	-	-	-	-	-	-	-
Net Interest Exp.	308.70	313.30	333.20	339.40	454.80	534.60	542.30	517.30	497.80	636.20	592.40
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	(3.50)	74.90	44.90	206.10	125.10	(0.50)	64.90	43.80	12.60	(5.80)	(1,790.70)
EBT Excl. Unusual Items	804.20	747.30	974.50	915.40	121.70	903.00	298.40	154.40	(721.20)	(664.40)	2,813.20
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	-	-	-	-	-	-	-	-
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	-	-	-	-	-	-	-	-	-	-	-
Other Unusual Items	-	-	-	-	-	-	-	-	-	-	-
EBT Incl. Unusual Items	804.20	747.30	974.50	915.40	121.70	903.00	298.40	154.40	(721.20)	(664.40)	2,813.20
Income Tax Expense	161.20	120.80	41.40	67.70	(358.30)	207.00	(54.10)	137.60	(51.30)	604.70	734.60
Earnings from Cont. Ops.	643.00	626.50	933.10	847.70	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)	2,078.60
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	2.10	2.80	3.70	0.10	-	-	-	-	-	-	-
Net Income	640.90	623.70	929.40	847.60	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)	2,078.60
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
NI to Common Incl Extra Items	640.90	623.70	929.40	847.60	480.00	696.00	352.50	16.80	(669.90)	(1,269.10)	2,078.60
Abnormal Losses (Gains)	234.80	328.46	413.00	744.70	1,543.90	629.60	742.90	820.00	1,618.60	1,992.30	(568.10)
Tax Effect on Abnormal Items	(76.56)	(103.79)	(110.84)	(170.02)	(439.11)	(114.69)	(185.76)	57.21	(89.95)	742.12	377.07
NI to Common Excl. Extra Items	799.14	848.37	1,151.56	1,422.28	1,584.79	1,210.91	909.64	894.01	858.75	1,465.32	1,887.57
Per Share Items											
Basic EPS	1.54	1.63	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)	1.71
Basic EPS Excl. Extra Items	1.54	1.63	2.49	1.80	0.94	1.30	0.69	0.03	(1.11)	(1.05)	1.71
Weighted Avg. Basic Shares Out.	415.20	383.30	373.70	472.20	513.00	534.50	514.50	515.70	601.20	1,208.80	1,212.10
Diluted EPS	1.52	1.58	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)	1.71
Diluted EPS Excl. Extra Items	1.52	1.58	2.34	1.70	0.92	1.30	0.68	0.03	(1.11)	(1.05)	1.71
Weighted Avg. Diluted Shares Out.	420.20	394.50	398.00	497.40	520.50	536.70	516.50	516.50	601.20	1,208.80	1,217.40
Normalized Basic EPS	2.59	2.89	3.56	4.30	4.89	4.56	4.58	4.42	3.95	3.70	1.71
Normalized Diluted EPS	1.90	2.15	2.90	2.86	3.04	2.26	1.76	1.73	1.43	1.21	1.55
Dividends per Share	-	-	-	-	-	-	-	-	-	-	-
Payout Ratio %	-	-	-	-	-	-	-	-	-	-	27.99
Supplemental Items											
EBITA	1,495.80	1,499.20	1,746.40	2,306.90	1,965.20	2,955.30	2,736.00	2,566.30	1,796.30	4,060.60	4,383.90
EBIT	1,109.40	1,135.50	1,352.60	1,460.90	701.60	1,437.10	905.60	715.50	(210.80)	(34.00)	1,614.90
As Reported Total Revenue*	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70
Effective Tax Rate %	20.04	16.16	4.25	7.40	-	22.92	-	89.12	-	-	26.11
Normalized Net Income	799.14	848.37	1,151.56	1,422.28	1,584.79	1,210.91	909.64	894.01	858.75	1,465.32	1,887.57
Interest Capitalized	-	-	-	-	-	-	-	-	-	-	-
Supplemental Operating Expense Items											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	42.60	47.00	66.00	92.80	88.90	74.70	(3.30)	56.80	79.20	111.20	116.40
Stock-Based Comp., Total	42.60	47.00	66.00	92.80	88.90	74.70	(3.30)	56.80	79.20	111.20	116.40

Ticker:	Vtrs US EQUITY
Period Type	Annuals

Vtrs US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Balance Sheet											
Balance Sheet as of:	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
ASSETS											
Cash And Equivalents	349.97	291.30	225.50	1,236.00	998.80	292.10	388.10	475.60	844.40	701.20	1,259.90
Short Term Investments	-	-	-	-	83.70	76.70	25.00	26.80	39.10	38.20	35.30
Total Cash & ST Investments	349.97	291.30	225.50	1,236.00	1,082.50	368.80	413.10	502.40	883.50	739.40	1,295.20
Accounts & Notes Receivable	1,554.34	1,820.00	2,268.50	2,689.10	3,015.40	3,173.10	2,416.50	2,640.10	3,891.30	3,774.40	3,243.80
Total Receivables	1,554.34	1,820.00	2,268.50	2,689.10	3,015.40	3,173.10	2,416.50	2,640.10	3,891.30	3,774.40	3,243.80
Inventories	1,525.24	1,656.90	1,651.40	1,951.00	2,456.40	2,542.70	2,580.20	2,670.90	5,471.90	3,977.70	3,519.50
Prepaid Exp.	243.82	452.90	2,295.80	596.60	756.40	766.10	518.40	552.00	1,707.40	1,957.60	1,811.20
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	229.35	250.10	-	-	211.80	362.60	439.50	391.90	913.40	453.80	765.70
Total Current Assets	3,902.72	4,471.20	6,441.20	6,472.70	7,522.50	7,213.30	6,367.70	6,757.30	12,867.50	10,902.90	10,635.40
Net Property, Plant & Equipment	1,397.22	1,665.50	1,785.70	1,983.90	2,322.20	2,339.10	2,170.20	2,404.20	3,783.50	3,479.40	3,283.80
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	87.66	77.80	397.40	457.60	633.20	496.80	572.20	703.10	2,147.90	1,332.70	925.90
Other Long-Term Assets	6,544.31	9,080.30	7,196.20	13,353.50	24,248.30	25,757.10	23,624.80	21,390.90	42,754.10	39,127.80	35,177.10
Total Assets	11,931.90	15,294.80	15,820.50	22,267.70	34,726.20	35,806.30	32,734.90	31,255.50	61,553.00	54,842.80	50,022.20
LIABILITIES											
Accrued Exp.	-	-	-	-	-	-	-	-	-	-	-
Short-term Borrowings	397.04	443.40	2,803.60	1,078.30	336.40	1,855.40	701.70	1,584.80	3,502.30	3,457.20	1,339.70
Accounts Payable	777.91	1,072.80	905.60	1,109.60	1,348.10	1,452.50	1,617.00	1,528.10	1,904.20	1,657.40	1,766.60
Curr. Income Taxes Payable	33.73	49.70	160.70	92.40	97.70	112.90	121.50	213.00	288.60	236.90	279.60
Other Current Liabilities	984.83	1,398.10	1,434.10	1,841.90	3,258.50	2,964.50	2,147.60	2,243.20	4,867.80	4,532.90	3,360.30
Total Current Liabilities	2,193.50	2,964.00	5,304.00	4,122.20	5,040.70	6,385.30	4,587.80	5,569.10	10,562.90	9,884.40	6,746.20
Long-Term Debt	4,700.90	7,586.50	3,846.40	6,295.60	15,202.90	12,865.30	13,161.20	11,390.00	22,658.70	19,918.00	18,196.60
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	1,681.67	1,784.40	3,394.10	2,084.10	3,365.00	3,248.10	2,818.80	2,412.60	5,377.30	4,547.70	4,007.10
Total Liabilities	8,576.07	12,334.90	12,544.50	12,501.90	23,608.60	22,498.70	20,567.80	19,371.70	38,598.90	34,350.10	28,949.90
Pref. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
Total Pref. Equity	-	-	-	-	-	-	-	-	-	-	-
Minority Interest	15.11	18.10	20.10	1.40	1.40	-	-	-	-	-	-
Additional Paid In Capital	4,256.58	4,375.60	4,486.10	7,134.10	8,505.30	8,592.00	8,597.40	8,649.60	18,450.90	18,548.20	18,657.90
Retained Earnings	2,061.37	2,685.10	3,614.50	4,462.10	4,942.10	5,644.50	6,010.70	6,031.10	5,361.20	3,688.80	5,175.60
Treasury Stock	(2,890.73)	(3,878.80)	(3,857.70)	(67.50)	(67.50)	(567.70)	(999.70)	(999.70)	-	-	-
Comprehensive Inc. and Other	(86.50)	(240.10)	(987.00)	(1,764.30)	(2,263.70)	(361.20)	(1,441.30)	(1,797.20)	(858.00)	(1,744.30)	(2,761.20)
Total Common Equity	3,355.83	2,959.90	3,276.00	9,765.80	11,117.60	13,307.60	12,167.10	11,883.80	22,954.10	20,492.70	21,072.30
Total Equity	3,355.83	2,959.90	3,276.00	9,765.80	11,117.60	13,307.60	12,167.10	11,883.80	22,954.10	20,492.70	21,072.30
Total Liabilities And Equity	11,931.90	15,294.80	15,820.50	22,267.70	34,726.20	35,806.30	32,734.90	31,255.50	61,553.00	54,842.80	50,022.20
Supplemental Items											
Total Shares Out. on Filing Date	395.21	371.60	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90	1,209.51	1,213.79
Total Shares Out. on Balance Sheet Date	395.21	371.60	375.22	490.62	535.33	524.21	515.80	516.15	1,206.90	1,209.51	1,213.79
Book Value/Share	8.45	7.92	8.68	19.90	20.77	25.39	23.59	23.02	19.02	16.94	17.36
Tangible Book Value	(2,399.39)	(3,916.60)	(3,140.50)	(2,837.60)	(12,563.00)	(12,143.90)	(11,245.30)	(9,356.70)	(19,076.10)	(17,755.20)	(11,960.60)
Tangible Book Value/Share	(6.07)	(10.54)	(8.37)	(5.78)	(23.47)	(23.17)	(21.80)	(18.13)	(15.81)	(14.68)	(9.85)
Total Debt	5,097.93	8,029.90	6,650.00	7,373.90	15,539.30	14,720.70	13,862.90	12,974.80	26,161.00	23,375.20	19,536.30
Net Debt	4,747.96	7,738.60	6,424.50	6,137.90	14,456.80	14,351.90	13,449.80	12,472.40	25,277.50	22,635.80	18,241.10
Total Minority Interest	15.11	18.10	20.10	1.40	1.40	-	-	-	-	-	-
Inventory Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	455.96	482.80	549.50	592.40	783.40	895.50	955.70	886.80	958.40	922.40	571.50
Work in Progress Inventory	268.19	310.00	298.40	387.00	436.00	384.70	369.90	417.20	1,438.10	993.30	755.40
Finished Goods Inventory	801.09	864.10	803.50	971.60	1,237.00	1,262.50	1,254.60	1,366.90	3,075.40	2,062.00	2,192.60
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	23.04	24.60	25.70	33.60	59.00	75.30	98.20	72.80	159.90	154.50	114.70
Full Time Employees	-	20,000.00	30,000.00	35,000.00	35,000.00	35,000.00	35,000.00	35,000.00	45,000.00	37,000.00	37,000.00

Bloomberg Company In Depth Fundamentals - Capital Structure Summary

Ticker: **Vtrs US EQUITY** | Sort: **Ascend** | Currency: **USD** | Reporting: **Change** | **USD**
 Period Type: **Quarters** | Consolidated: **Yes** | Accounting: **Mixed**

Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

WACC	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
For the Fiscal Period Ending	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023
	%	%	%	%	%
Equity					
Cost of Equity	10.2%	9.1%	8.9%	8.5%	8.9%
Weight of Equity	37.2%	37.4%	33.8%	40.9%	37.7%
+ Debt					
Cost of Debt	1.9%	3.7%	4.0%	4.3%	3.8%
Weight of Debt	62.8%	62.6%	66.2%	59.1%	62.3%
+ Preferred Equity					
Cost of Pref Equity	0.0%	0.0%	0.0%	0.0%	0.0%
Weight of Pref Equity	0.0%	0.0%	0.0%	0.0%	0.0%
WACC	5.0%	5.7%	5.7%	6.0%	5.7%

Capital Structure	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023	
For the Fiscal Period Ending	USD	USD	USD	USD	USD	
Currency	Millions	% of Total	Millions	% of Total	Millions	
Net Market Cap	3,351.4	9.4%	1,871.3	5.5%	1,349.4	4.4%
CT Reinvestments	18,954.2	53.4%	19,398.6	57.1%	18,903.8	61.8%
Pref Equity	0.0	0.0%	0.0	0.0%	0.0	0.0%
Total Capital	35,495.7	100.0%	33,964.2	100.0%	30,585.0	100.0%

Debt Summary Data	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023	
For the Fiscal Period Ending	USD	USD	USD	USD	USD	
Currency	Millions	% of Total	Millions	% of Total	Millions	
Total Financials Due*	1,650.0	7.4%	1,650.0	7.8%	300.4	1.5%
Total Revolving Credit	4,000.0	17.9%	4,000.0	18.8%	3,300.0	16.3%
Total Capital Leases	--	--	--	--	0.0	0.0%
General/Other Borrowings	--	--	73.4%	16,652.8	62.2%	71.1%
Total Principal Due	22,305.6	100.0%	21,269.9	100.0%	19,536.3	100.0%
Total Debt Outstanding	22,305.6		21,269.9		19,536.3	

Additional Totals	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023	
Currency	Millions	% of Total	Millions	% of Total	Millions	
Total Cash & CT Investments	789.0	3.5%	700.2	3.3%	681.2	3.4%
Net Debt	21,516.6	96.5%	20,569.7	96.7%	19,572.0	96.6%
Total Short-Term Borrowings	3,351.4	15.0%	1,871.3	8.8%	1,349.4	6.7%
Curr. Port. of LT Debt/Cap. Leases	2,696.0	12.1%	851.6	4.0%	849.0	4.2%
Long-Term Debt (incl. Cap. Leases)	18,954.2	85.0%	19,398.6	91.2%	18,903.8	93.3%
Total Secured Debt	--	--	--	--	--	--
Fixed Rate Debt	--	--	--	--	--	--
Variable Rate Debt	--	--	--	--	--	--
Credit Ratios						
Net Debt/EBITDA	4.5x	4.3x	4.2x	3.9x	4.3x	
Total Debt/EBITDA	4.7x	4.5x	4.4x	4.2x	4.4x	
Cooperative Income/Total Debt	0.0x	0.0x	0.0x	0.0x	0.0x	
LTM FCF/Total Debt	0.1x	0.1x	0.1x	0.1x	0.1x	
LTM FFF/Total Debt	0.1x	0.2x	0.2x	0.2x	0.1x	
FRIT/Interest Expense	4.8x	3.8x	3.7x	-1.4x	2.7x	
FRIT/Total Interest Expense	4.8x	3.8x	3.7x	-1.4x	2.7x	
Degree of Financial Leverage	1.3x	1.4x	1.4x	--	1.6x	
EBITDA-CAPEX/Interest Expense	9.4x	8.1x	7.5x	3.5x	7.4x	
EBITDA/Total Interest Expense	9.0x	8.7x	8.2x	4.5x	7.7x	

Debt Schedule	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023	
Currency	Millions	% of Total	Millions	% of Total	Millions	
Debt Schedule in Yr 1	--	--	0.0	0.0%	1,250.0	3.3%
Debt Schedule in Yr 2	--	--	1,250.0	6.4%	1,873.0	4.9%
Debt Schedule in Yr 3	--	--	1,715.0	8.8%	1,285.0	3.4%
Debt Schedule in Yr 4	--	--	1,250.0	6.4%	2,550.0	7.0%
Debt Schedule in Yr 5	--	--	3,226.0	16.6%	1,660.0	4.4%
Debt Schedule - Years 2 - 3	--	--	2,965.0	15.2%	3,158.0	8.3%
Debt Schedule - Years 4 - 5	--	--	4,466.0	22.9%	4,215.0	11.1%
Debt Schedule - Years 2 - 5	--	--	7,431.0	38.1%	7,373.0	19.4%
Debt Schedule Beyond Yr 5	--	--	11,493.0	59.0%	10,091.0	26.6%
Debt Schedule - Total Debt	21,368.6	100.0%	19,965.0	100.0%	19,488.3	100.0%

Capital Lease Schedule	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023
Currency	Millions	% of Total	Millions	% of Total	Millions
Capital Leases - Year 1	--	--	--	--	--
Capital Leases - Year 2	--	--	--	--	--
Capital Leases - Year 3	--	--	--	--	--
Capital Leases - Year 4	--	--	--	--	--
Capital Leases - Year 5	--	--	--	--	--
Capital Leases - Years 2 - 3	--	--	--	--	--
Capital Leases - Years 4 - 5	--	--	--	--	--
Capital Leases - Years 2 - 5	--	--	--	--	--
Capital Leases Beyond Year 5	--	--	--	--	--
Total Future Value of Capital Leases	--	--	--	0.0	0.0
Present Value of ST Capital Leases	--	--	--	--	--
Present Value of LT Capital Leases	--	--	--	0.0	--

Operative Leases (Rental Expense) Schedule	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023	
Currency	Millions	% of Total	Millions	% of Total	Millions	
Rental Expense - Year 1	--	--	--	--	76.4	26.9%
Rental Expense - Year 2	--	--	--	--	63.4	22.3%
Rental Expense - Year 3	--	--	--	--	38.6	13.6%
Rental Expense - Year 4	--	--	--	--	30.2	10.6%
Rental Expense - Year 5	--	--	--	--	23.1	8.1%
Rental Expense - Years 2 - 3	--	--	--	--	102.0	35.9%
Rental Expense - Years 4 - 5	--	--	--	--	53.3	18.8%
Rental Expense - Years 2 - 5	--	--	--	--	155.3	54.7%
Rental Expense Beyond Year 5	--	--	--	--	52.3	18.4%
Total Sublease Income	--	--	--	--	--	--
Future Min Oper Lease Obligations	--	--	--	--	284.0	100.0%

Contractual Obligation Schedule	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023
Currency	Millions	% of Total	Millions	% of Total	Millions
Contractual Obligations - Year 1	--	--	--	--	--
Contractual Obligations - Years 2-3	--	--	--	--	--
Contractual Obligations - Years 4-5	--	--	--	--	--
Contractual Obligations - Years 2 - 5	--	--	--	--	--
Contractual Obligations - Beyond Year 5	--	--	--	--	--
Total Contractual Obligations	--	--	--	--	--

Purchase Obligations	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023
Currency	Millions	% of Total	Millions	% of Total	Millions
Purchase Obligations	--	--	--	--	--

Interest Rate Data	31/03/2022	30/06/2022	30/09/2022	31/12/2022	31/03/2023
Currency	Millions	% of Total	Millions	% of Total	Millions
W/Avg. Interest Rate - Long-term Debt	--	--	--	--	--

Ticker: Vtrs US EQUITY	Vtrs US EQUITY	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Accounting	Mixed		

Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022
REVENUE											
Revenue by Product											
For the Fiscal Period Ending											
Revenue	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70
Brands	5,946.20	5,900.70	6,510.40	9,429.30	10,967.10	11,760.00	11,268.70	5,362.10	5,289.50	10,841.30	9,889.60
Generics	849.90	1,008.50	51.10	-	109.80	-	165.20	4,796.90	5,234.90	5,630.20	5,015.10
Complex Generics & Biosimilars	-	-	-	-	-	-	-	1,211.30	1,295.50	1,342.10	1,313.40
Other Sources	-	-	-	-	-	-	-	-	126.10	72.70	44.60
#N/A Field Not Applicable	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022
Revenue by Geography											
For the Fiscal Period Ending											
Revenue	6,796.10	6,909.10	7,719.60	9,429.30	11,076.90	11,907.70	11,433.90	11,500.50	11,946.00	17,886.30	16,262.70
Developed Markets	4,060.70	3,988.30	4,548.40	5,100.40	5,629.50	4,969.60	4,157.30	-	8,510.90	10,428.70	9,768.90
Emerging Markets	1,391.90	1,438.60	1,621.30	2,205.60	2,953.80	3,958.30	4,095.60	-	1,853.80	3,144.70	2,615.60
	1,297.60	1,429.70	1,476.80	2,056.60	2,383.80	2,832.10	3,015.80	-	1,195.30	2,212.80	2,201.20
	45.90	52.50	73.10	66.70	109.80	147.70	165.20	-	259.90	2,027.40	1,632.40
	-	-	-	-	-	-	-	-	126.10	72.70	44.60
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-
	-	-	-	-	-	-	-	-	-	-	-

GROSS PROFIT BEF TAX

OPERATING PROFIT BEF TAX

Ticker:	Vtrs US EQUITY	Sort	Ascend	Currency	Reporting	Change	USD
Period Type	Annuals	Consolidated	Yes	Accounting	Mixed		

Viatrix Inc

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Pension											
For the Fiscal Period Ending	31/12/2012	31/12/2013	31/12/2014	31/12/2015	31/12/2016	31/12/2017	31/12/2018	31/12/2019	31/12/2020	31/12/2021	31/12/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
Pension Net Periodic Cost											
Service Cost	--	--	5.00	11.90	17.40	20.10	19.20	20.70	23.50	38.60	32.60
Interest Cost	--	--	2.60	4.00	8.20	13.60	13.00	13.60	13.50	31.60	36.80
Expected Return on Plan Assets	--	--	(1.70)	(6.40)	(10.90)	(14.30)	(14.40)	(12.10)	(19.90)	(66.10)	(64.60)
Pension Expense (Income)	-	-	7.00	11.80	13.40	18.20	17.90	22.00	18.60	(10.20)	7.80
Other Postretirement Cost											
Service Cost	--	--	0.50	0.60	0.60	0.70	0.60	0.60	1.20	3.40	3.40
Interest Cost	--	--	1.00	1.10	1.30	1.60	1.50	1.50	1.40	2.60	3.70
Expected Return on Plan Assets	--	--	-	-	-	-	-	-	-	-	-
Other Postretirement Benefits Expense (I	-	-	-	-	-	-	2.30	5.50	2.90	6.20	2.90
Pension Funded Status											
Fair Value of Plan Assets	--	--	--	162.00	291.70	296.10	283.50	315.70	1,354.60	1,366.40	1,067.10
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	--	--	28.90	26.40	58.20	97.00	25.60
Benefits Paid	--	--	--	--	--	--	(24.90)	(23.90)	(24.60)	(52.80)	(54.10)
Projected Benefit Obligation	--	--	--	234.40	632.90	665.20	635.40	674.70	2,145.80	1,946.60	1,379.00
Over(Under) Funded Pension	--	--	--	(72.40)	(341.20)	(369.10)	(351.90)	(359.00)	(791.20)	(580.20)	(311.90)
Accumulated Benefit Obligation	--	--	--	--	--	--	--	--	--	--	--
Pension Funding Ratio	--	--	--	69.11	46.09	44.51	44.62	46.79	63.13	70.19	77.38
Other Postretirement Funded Status											
Fair Value of Plan Assets	--	--	--	-	-	-	-	-	-	-	-
Actual Return (Loss) on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Employer Contribution	--	--	--	--	--	--	2.50	9.40	1.70	18.30	10.20
Benefits Paid	--	--	(1.60)	(2.00)	(2.20)	(2.70)	(2.70)	(2.50)	(1.60)	(20.70)	(14.70)
Projected Benefit Obligation	--	--	--	--	--	--	34.00	33.80	188.80	188.40	137.50
Over(Under) Funded Post Ret Benefits	--	--	--	(26.00)	(38.00)	(35.10)	(34.00)	(33.80)	(188.80)	(188.40)	(137.50)
Other Post-Retirement Funding Ratio	--	--	--	--	--	--	-	-	-	-	-
Actuarial Assumptions											
Pension											
Expected Return on Plan Assets	--	--	--	--	--	--	4.90	4.30	4.30	5.10	5.00
Discount Rate used on Plan Liabilities	--	--	--	--	--	--	2.30	1.60	1.90	2.30	4.80
Rate of Compensation Increase	--	--	--	--	--	--	2.90	2.90	2.90	3.10	3.70
Other Postretirement Benefits											
Expected Return on Plan Assets	--	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	--	--	--	--	--	--	3.70	4.30	3.30	1.90	2.30
Health Care Cost Trend Projected(next y	--	--	--	--	--	--	--	--	--	--	--
Pension Plan Asset Allocation											
Fair Value of Plan Assets	--	--	--	162.00	291.70	296.10	283.50	315.70	1,354.60	1,366.40	1,067.10
Asset Category - Equities %	--	--	--	--	--	--	43.92	28.29	45.28	40.33	37.14
Asset Category - Debt %	--	--	--	--	--	--	43.67	56.98	43.70	45.15	42.46
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	--	--	1.38	1.24	3.82	4.76	3.29
Asset Category - Other %	--	--	--	--	--	--	11.04	13.49	7.19	9.76	17.11
Expected Pension Payments											
Year 1	--	--	--	--	--	--	32.00	33.20	104.50	101.80	93.10
Year 2	--	--	--	--	--	--	34.20	34.00	102.30	97.10	96.10
Year 3	--	--	--	--	--	--	35.70	34.70	104.90	103.00	97.90
Year 4	--	--	--	--	--	--	34.00	35.20	108.60	100.70	98.30
Year 5	--	--	--	--	--	--	36.40	38.90	106.90	104.30	102.00
Beyond Year 5	--	--	--	--	--	--	192.10	193.10	526.20	528.50	518.10
Expected Postretirement Benefits											
Year 1	--	--	--	--	--	--	1.70	2.00	16.40	16.10	15.40
Year 2	--	--	--	--	--	--	1.70	1.80	16.60	16.50	15.80
Year 3	--	--	--	--	--	--	2.00	1.90	16.50	16.90	15.80
Year 4	--	--	--	--	--	--	2.30	1.90	16.60	16.80	15.70
Year 5	--	--	--	--	--	--	2.20	2.00	16.30	16.60	15.10
Beyond Year 5	--	--	--	--	--	--	11.60	10.20	71.40	73.00	64.50

